CluePoints’ Site Profile & Oversight Tool (SPOT) shortlisted as finalist in 2024 Citeline Awards
RBQM leader accruing annual awards with latest running for Best Sponsor-facing Technology Initiative
King of Prussia, PA – March 25th, 2024: CluePoints, providers of best-in-class statistical and AI-driven software solutions, has been shortlisted as finalist for the Best Sponsor-facing Technology Initiative
in the 2024 Citeline Awards. CluePoints was recognized for its Site Profile & Oversight Tool (SPOT), - due to launch to the market in June 2024 – and was developed collaboratively, based on market needs, with two large pharmaceutical clients of CluePoints who helped provide direction and feedback regarding the required features and functionalities. The Citeline Awards, which recognize and celebrate clinical trial and R&D achievements in pharmaceutical, biotech, CRO and allied industries in 2023, will announce the Winners on May 8th, 2024.
SPOT is a site profiling tool that takes Risk Based Monitoring to the next level. SPOT enables adaptive site monitoring thus improving the overall efficiency of clinical trials, supporting study teams to align data verification and review efforts and the scheduling of the type and date of the next monitoring visits with each site’s specific needs and risks. It circumvents rigid source data review strategies, reduces unnecessary monitoring efforts, and prioritizes the use of monitoring resources where they are needed most.
François Torche, Co-Founder and Chief Product and Technology Officer of CluePoints, commented, “CluePoints is extremely proud to again be in the running for a Citeline Award, recognizing our achievements for a Sponsor-facing Technology Initiative. As a company that takes considerable pride in our team’s innovative work, gaining recognition year over year for the strides we are making is not only rewarding but validates that we are meeting the needs of the industry we serve. Whilst recognizing the combined efforts of the team at CluePoints, I would like to pay special tribute for our continuing success to Adrien Lebrun, who has been a key contributor over the years but has recently very sadly passed away recently.”
This accolade could prove a double victory for CluePoints in the annual Citeline Awards, having previously won the 2021 Citeline Award for Excellence in Innovation in Response to COVID-19 – Clinical Trial Activities. CluePoints were also very recently award winners for their game-changing ‘Audit Trail Review’ which secured the ACDM 2024 Award Accolade for Innovation in the Management of Clinical Data.
To learn more about CluePoints award winning solutions, please visit www.cluepoints.com
-END-
For Editors:
About SPOT
About the Citeline Awards
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. Our products utilize comprehensive statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints® is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation you now have everything you need to adhere with global regulatory guidance. The result is increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
Editor Details
-
Company:
- Discovery PR
-
Name:
- Sophie Beattie
- Email:
-
Telephone:
- +441606889194
- Website:
Related Links
- Website: CluePoints